Blended Interferon-Alpha and Interleukin-2 Preparation
A mixed solution of recombinant interferon-alpha (IFN-α) and interleukin-2 (IL-2) for immunotherapy in viral infections and cancer. Falls under HTS 3002.14.00 as mixed immunological products (interferons and interleukins) not prepared for retail sale or in measured doses.
Import Duty Rates by Country of Origin
More Specific Codes
This product may fall under a more specific subheading:
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If unmixed, such as pure IFN-α
Chapter note (a) treats unmixed products of Chapter 28/29 separately from mixed under 3002.14.
If for opacifying or diagnostic reagent use in measured doses
Diagnostic immunological mixes in measured doses shift to 3006 per specific heading scope.
If classified as general diagnostic reagents
Chapter excludes diagnostic reagents of 3822; non-immunological lab reagents go there.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• Submit lab reports confirming mixture of immunological proteins like IFN and IL-2, not simple solutions
• Ensure cold chain compliance with temperature logs; FDA prior notice required for biological imports
Related Products under HTS 3002.14.00
Colony Stimulating Factor and Interferon Mix
Bulk blend of CSF and IFN for enhancing immune response in chemotherapy patients. Fits 3002.14.00 as mixed immunological products (CSF, IFN) not put up for retail.
Mixed Interleukin and TNF Preparation
Combined IL and TNF modulators for rheumatoid arthritis therapy in bulk form. 3002.14.00 for mixed interleukins/TNF immunologicals.
Biotech Antibody and Chemokine Solution
Mixed MAB and chemokine solution for inflammation control. HTS 3002.14.00 applies.
Growth Factor and MAB Blend
Bulk GF-MAB mix for wound healing immunology.
Hematopoietin Antibody Cocktail
Mixed hematopoietin and antibody for blood disorders.
Mixed Monoclonal Antibody Cocktail for Cancer Therapy
A blended preparation of multiple monoclonal antibodies (MABs) such as trastuzumab and pertuzumab for targeted cancer immunotherapy. Classified under HTS 3002.14.00 as mixed immunological products not in measured doses or retail packaging, involving peptides and proteins regulating immunological processes.